Los Angeles, CA - May 22, 2025 – Scientists at the Terasaki Institute for Biomedical Innovation (TIBI), led by Dr. Vadim Jucaud (Assistant Professor), have engineered a novel multi-cellular 3D glioblastoma (GBM) in vitro model that mimics the biomechanical properties of brain tissue and the role of pericytes in glioblastoma (GBM) resistance to temozolomide (TMZ), the standard-of-care chemotherapy for this deadly brain cancer.